{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T08:07:49Z","timestamp":1779091669396,"version":"3.51.4"},"reference-count":35,"publisher":"Tsinghua University Press","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.26599\/1671-5411.2026.04.003","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T07:33:26Z","timestamp":1779089606000},"page":"246-256","source":"Crossref","is-referenced-by-count":0,"title":["Rationale and design of the Early Initiation of Intensification Lipid-Lowering Treatment in Acute Coronary Syndrome (ELITE-ACS): a real-world study"],"prefix":"10.26599","volume":"23","author":[{"given":"Ya-Ni","family":"YU","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"WANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Dan","family":"TUO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zong-Xing","family":"LI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan-Dan","family":"LI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Dai","family":"CHEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11138","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"RA Byrne","year":"2023","unstructured":"RA Byrne. 2023 ESC guidelines for the management of acute coronary syndromes. 2023, 44: 3720-3826.","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e018897","DOI":"10.1161\/JAHA.120.018897","article-title":"Lipid management in patients presenting with acute coronary syndromes: a review","volume":"9","author":"BE Claessen","year":"2020","unstructured":"BE Claessen. Lipid management in patients presenting with acute coronary syndromes: a review. 2020, 9: e018897.","journal-title":"J Am Heart Assoc"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"T Jernberg","year":"2015","unstructured":"T Jernberg. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. 2015, 36: 1163-1170.","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1093\/eurheartj\/ehaa034","article-title":"Application of the 2019 ESC\/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study","volume":"41","author":"A Allahyari","year":"2020","unstructured":"A Allahyari. Application of the 2019 ESC\/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study. 2020, 41: 3900-3909.","journal-title":"Eur Heart J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ehjacc\/zuac123","author":"","unstructured":"","journal-title":"null"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e46605","DOI":"10.7759\/cureus.46605","article-title":"PCSK-9 inhibitors and cardiovascular outcomes: a systematic review with meta-analysis","volume":"15","author":"AP Bodapati","year":"2023","unstructured":"AP Bodapati. PCSK-9 inhibitors and cardiovascular outcomes: a systematic review with meta-analysis. 2023, 15: e46605.","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"GG Schwartz. Alirocumab and cardiovascular outcomes after acute coronary syndrome. 2018, 379: 2097-2107.","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.diabet.2017.07.009","article-title":"Circulating PCSK9 levels in acute coronary syndrome: results from the PC-SCA-9 prospective study","volume":"43","author":"B Cariou","year":"2017","unstructured":"B Cariou. Circulating PCSK9 levels in acute coronary syndrome: results from the PC-SCA-9 prospective study. 2017, 43: 529-535.","journal-title":"Diabetes Metab"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"939791","DOI":"10.3389\/fcvm.2022.939791","article-title":"Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: a pilot study on Chinese patients","volume":"9","author":"Z Ou","year":"2022","unstructured":"Z Ou. Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: a pilot study on Chinese patients. 2022, 9: 939791.","journal-title":"Front Cardiovasc Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/1744666X.2022.2017281","article-title":"The role of PCSK9 in inflammation, immunity, and autoimmune diseases","volume":"18","author":"J Frosteg\u00e5rd","year":"2022","unstructured":"J Frosteg\u00e5rd. The role of PCSK9 in inflammation, immunity, and autoimmune diseases. 2022, 18: 67-74.","journal-title":"Expert Rev Clin Immunol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol level in patient with acute coronary syndromes (EVOPACS)","volume":"74","author":"KC Koskinas","year":"2019","unstructured":"KC Koskinas. Evolocumab for early reduction of LDL cholesterol level in patient with acute coronary syndromes (EVOPACS). 2019, 74: 2452-2462.","journal-title":"J Am Coll Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"621","DOI":"10.26599\/1671-5411.2023.09.008","article-title":"2023 China guidelines for lipid management","volume":"20","author":"JJ Li","year":"2023","unstructured":"JJ Li. 2023 China guidelines for lipid management. 2023, 20: 621-663.","journal-title":"J Geriatr Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.atherosclerosis.2013.12.003","article-title":"The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: results of the CHILLAS trial","volume":"233","author":"SP Zhao","year":"2014","unstructured":"SP Zhao. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: results of the CHILLAS trial. 2014, 233: 707-712.","journal-title":"Atherosclerosis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.jacc.2012.12.047","article-title":"Standardized cardiovascular data for clinical research, registries, and patient care: a report from the Data Standards Workgroup of the National Cardiovascular Research Infrastructure project","volume":"61","author":"HV Anderson","year":"2013","unstructured":"HV Anderson. Standardized cardiovascular data for clinical research, registries, and patient care: a report from the Data Standards Workgroup of the National Cardiovascular Research Infrastructure project. 2013, 61: 1835-1846.","journal-title":"J Am Coll Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12872-024-04401-0","article-title":"Predictive value of the perivascular fat attenuation index for MACE in young people suspected of CAD","volume":"25","author":"Y Yu","year":"2025","unstructured":"Y Yu. Predictive value of the perivascular fat attenuation index for MACE in young people suspected of CAD. 2025, 25: 80.","journal-title":"BMC Cardiovasc Disord"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"138","author":"K Thygesen","year":"2018","unstructured":"K Thygesen. Fourth universal definition of myocardial infarction (2018). 2018, 138: e618-e651.","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1001\/jamacardio.2023.2741","article-title":"Modification of the GRACE risk score for risk prediction in patients with acute coronary syndromes","volume":"8","author":"G Georgiopoulos","year":"2023","unstructured":"G Georgiopoulos. Modification of the GRACE risk score for risk prediction in patients with acute coronary syndromes. 2023, 8: 946-956.","journal-title":"JAMA Cardiol"},{"key":"ref18","first-page":"e771","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"151","author":"SV Rao","year":"2025","unstructured":"SV Rao. 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. 2025, 151: e771-e862.","journal-title":"Circulation"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.22541\/au.159554641.10759874","article-title":"Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study)","volume":"18","author":"YQ Liu","year":"2021","unstructured":"YQ Liu. Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study). 2021, 18: 261-270.","journal-title":"J Geriatr Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"988576","DOI":"10.3389\/fcvm.2022.988576","article-title":"Achievement of low-density lipoprotein cholesterol targets in Chinese patients with atherosclerotic cardiovascular disease after receiving statins and ezetimibe","volume":"9","author":"Y Cheng","year":"2022","unstructured":"Y Cheng. Achievement of low-density lipoprotein cholesterol targets in Chinese patients with atherosclerotic cardiovascular disease after receiving statins and ezetimibe. 2022, 9: 988576.","journal-title":"Front Cardiovasc Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"L R\u00e4ber","year":"2022","unstructured":"L R\u00e4ber. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. 2022, 327: 1771-1781.","journal-title":"JAMA"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.clinthera.2011.08.002","article-title":"Impact of ezetimibe coadministered with statins on cardiovascular events following acute coronary syndrome: a 3-year population-based retrospective cohort study in Taiwan","volume":"33","author":"CF Lin","year":"2011","unstructured":"CF Lin. Impact of ezetimibe coadministered with statins on cardiovascular events following acute coronary syndrome: a 3-year population-based retrospective cohort study in Taiwan. 2011, 33: 1120-1131.","journal-title":"Clin Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/clc.23725","article-title":"Lipid goal attainment in post-acute coronary syndrome patients in China: results from the 6-month real-world dyslipidemia international study II","volume":"44","author":"Y Gong","year":"2021","unstructured":"Y Gong. Lipid goal attainment in post-acute coronary syndrome patients in China: results from the 6-month real-world dyslipidemia international study II. 2021, 44: 1575-1585.","journal-title":"Clin Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ahj.2019.02.019","article-title":"Prehospital statin use and low-density lipoprotein cholesterol levels at admission in acute coronary syndrome patients with history of myocardial infarction or revascularization: findings from the Improving Care for Cardiovascular Disease in China (CCC) project","volume":"212","author":"Y Xing","year":"2019","unstructured":"Y Xing. Prehospital statin use and low-density lipoprotein cholesterol levels at admission in acute coronary syndrome patients with history of myocardial infarction or revascularization: findings from the Improving Care for Cardiovascular Disease in China (CCC) project. 2019, 212: 120-128.","journal-title":"Am Heart J"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2020.05.022","article-title":"Two-year outcomes post-discharge in Asian patients with acute coronary syndrome: findings from the EPICOR Asia study","volume":"315","author":"Y Huo","year":"2020","unstructured":"Y Huo. Two-year outcomes post-discharge in Asian patients with acute coronary syndrome: findings from the EPICOR Asia study. 2020, 315: 1-8.","journal-title":"Int J Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1136\/heartjnl-2020-317165","article-title":"Incidence, predictors, and prognostic impact of recurrent acute myocardial infarction in China","volume":"107","author":"J Song","year":"2020","unstructured":"J Song. Incidence, predictors, and prognostic impact of recurrent acute myocardial infarction in China. 2020, 107: 313-318.","journal-title":"Heart"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/ehjacc\/zuac123","author":"","unstructured":"","journal-title":"null"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"11079","DOI":"10.1038\/s41598-019-47242-0","article-title":"Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden","volume":"9","author":"S Schuster","year":"2019","unstructured":"S Schuster. Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden. 2019, 9: 11079.","journal-title":"CETP mice. Sci Rep"},{"key":"ref29","first-page":"5129","article-title":"PCSK9 inhibitors suppress oxidative stress and inflammation in atherosclerotic development by promoting macrophage autophagy","volume":"15","author":"J Yang","year":"2023","unstructured":"J Yang. PCSK9 inhibitors suppress oxidative stress and inflammation in atherosclerotic development by promoting macrophage autophagy. 2023, 15: 5129-5144.","journal-title":"Am J Transl Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"rbac103","DOI":"10.1093\/rb\/rbac103","article-title":"Tuning macrophages for atherosclerosis treatment","volume":"10","author":"F Fang","year":"2022","unstructured":"F Fang. Tuning macrophages for atherosclerosis treatment. 2022, 10: rbac103.","journal-title":"Regen Biomater"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"118540","DOI":"10.1016\/j.atherosclerosis.2024.118540","article-title":"Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: a meta-analysis of 60 randomized controlled trials","volume":"396","author":"PM Burger","year":"2024","unstructured":"PM Burger. Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: a meta-analysis of 60 randomized controlled trials. 2024, 396: 118540.","journal-title":"Atherosclerosis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade","volume":"53","author":"G Lambert","year":"2012","unstructured":"G Lambert. The PCSK9 decade. 2012, 53: 2515-2524.","journal-title":"J Lipid Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/14656566.2019.1702970","article-title":"PCSK9 inhibitors for treating hypercholesterolemia","volume":"21","author":"A Pasta","year":"2020","unstructured":"A Pasta. PCSK9 inhibitors for treating hypercholesterolemia. 2020, 21: 353-363.","journal-title":"Expert Opin Pharmacother"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"SJ Nicholls","year":"2022","unstructured":"SJ Nicholls. Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction. 2022, 15: 1308-1321.","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e14345","DOI":"10.1111\/ijcp.14345","article-title":"Prognostic impact of comorbidity measures on outcomes following acute coronary syndrome: a systematic review","volume":"75","author":"F Zhang","year":"2021","unstructured":"F Zhang. Prognostic impact of comorbidity measures on outcomes following acute coronary syndrome: a systematic review. 2021, 75: e14345.","journal-title":"Int J Clin Pract"}],"container-title":["Journal of Geriatric Cardiology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T07:33:28Z","timestamp":1779089608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciopen.com\/article\/10.26599\/1671-5411.2026.04.003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"URL":"https:\/\/doi.org\/10.26599\/1671-5411.2026.04.003","relation":{},"ISSN":["1671-5411"],"issn-type":[{"value":"1671-5411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}